WO2012091023A1 - 培地およびキレート剤を含む水溶液の調製方法 - Google Patents
培地およびキレート剤を含む水溶液の調製方法 Download PDFInfo
- Publication number
- WO2012091023A1 WO2012091023A1 PCT/JP2011/080236 JP2011080236W WO2012091023A1 WO 2012091023 A1 WO2012091023 A1 WO 2012091023A1 JP 2011080236 W JP2011080236 W JP 2011080236W WO 2012091023 A1 WO2012091023 A1 WO 2012091023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous solution
- medium
- chelating agent
- membrane
- antibody
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2642—Aggregation, sedimentation, flocculation, precipitation or coagulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Definitions
- the present invention relates to a method for preparing an aqueous solution containing a medium and a chelating agent, an aqueous solution prepared by the preparation method, a method for culturing cells using the aqueous solution prepared by the preparation method, and a method for producing a physiologically active substance using the culture method ,
- a physiologically active substance produced using the production method a method for membrane filtration of an aqueous solution prepared by the method for preparing the aqueous solution, a method for improving the membrane filterability of an aqueous solution, or an aqueous solution prepared, and the aqueous solution as a membrane
- the present invention relates to a method for producing a physiologically active substance by culturing cells using the aqueous solution after filtration.
- Non-patent Document 1 Physiologically active substances, especially glycoproteins or antibodies, have recently been approved as various biopharmaceuticals, and more candidate substances are under development (Non-patent Document 1). For this reason, production of physiologically active substances such as glycoproteins and antibodies using cells is expected to become increasingly popular.
- Non-Patent Document 2 In preparation of an aqueous solution for cell culture that is indispensable for producing these physiologically active substances using cells, it is necessary to ensure the sterility of the medium for the safety of the product and the process. So far, 0.2 ⁇ m membrane filtration process for removing microorganisms has been widely used in the preparation of aqueous solution for cell culture, but it is recommended to use 0.1 ⁇ m membrane filtration process for the purpose of removing mycoplasma for several years. (Non-Patent Document 2). Therefore, good membrane permeability of an aqueous solution for cell culture is becoming more and more useful in industrialization, and is one problem.
- Non-patent Document 3 it is a problem in the pharmaceutical industry that biopharmaceuticals have higher production costs than low molecular weight drugs.
- Non-patent Document 3 efforts have been made to reduce costs by reinforcing productivity by adding some components, adding new components, or increasing the concentration of aqueous solutions for cell culture. Good membrane filtration is becoming more difficult.
- a highly versatile aqueous solution for cell culture that performs membrane filtration in an increasingly stable and short time.
- Patent Document 1 Non-Patent Document 4, and Non-Patent Document 5
- the improvement of membrane filterability of an aqueous solution for cell culture by increasing the membrane area is not industrially suitable due to cost and equipment limitations.
- the improvement of dissolution conditions has not led to a dramatic improvement in the filterability of aqueous solutions for cell culture.
- Chelating agents such as citric acid, malic acid or ethylenediaminetetraacetic acid are widely known as one of the components contained in an aqueous solution for cell culture (Patent Document 2 and Patent Document 3).
- Sialic acid is also known as a substance having a chelating action (Non-Patent Document 6).
- Non-Patent Document 6 there is no known method for improving the membrane filterability of an aqueous solution for cell culture using a chelating agent.
- the present invention provides a method for preparing an aqueous solution that achieves dramatic improvement in filterability, an aqueous solution prepared by the preparation method, a method for culturing cells using an aqueous solution prepared by the preparation method, A method for producing a physiologically active substance using a culture method, a physiologically active substance produced using the production method, a method for membrane filtration of an aqueous solution prepared by the method for preparing the aqueous solution, a method for improving the membrane filterability of an aqueous solution, Alternatively, a method for producing a physiologically active substance by preparing an aqueous solution, subjecting the aqueous solution to membrane filtration, and culturing cells using the aqueous solution is provided.
- the present invention is as follows. 1. A method for preparing an aqueous solution containing a medium and a chelating agent, comprising adding the chelating agent to the aqueous solution prior to final pH adjustment of the aqueous solution. 2. The preparation of the aqueous solution according to item 1 above, wherein the chelating agent is at least one selected from citric acid, malic acid, ethylenediaminetetraacetic acid, ethylenediaminetetraacetic acid iron (III) sodium salt and sialic acid, and salts or hydrates thereof. Method. 3. 3. The preparation method according to item 1 or 2, wherein the medium is a powder medium, a liquid medium, or a slurry medium. 4). 4.
- the preparation method according to item 3 wherein the powder medium is a medium further containing at least one selected from metal salts, sugars and vitamins. 5. 5. The preparation method according to any one of items 1 to 4, wherein the medium is a cell culture medium. 6). 6. The preparation method according to item 5 above, wherein the medium is a medium for animal cell culture. 7. 7. The preparation method according to item 6 above, wherein the medium is a medium for CHO cell culture derived from Chinese hamster ovary tissue. 8). 8. An aqueous solution prepared by the method according to any one of 1 to 7 above. 9. 8. A cell culture method using the aqueous solution prepared by the method according to any one of 1 to 7 above. 10. 10. The method for culturing cells according to item 9, wherein the cells are animal cells. 11.
- the method for culturing cells according to item 10 above, wherein the cells are CHO cells derived from Chinese hamster ovary tissue.
- 12 A method for producing a physiologically active substance, which uses the cell culture method according to any one of 9 to 11 above.
- the physiologically active substance is a peptide or protein.
- 14 The production method according to item 13 above, wherein the protein is a glycoprotein or an antibody. 15.
- a method for membrane filtration of an aqueous solution containing a medium and a chelating agent wherein the aqueous solution is an aqueous solution prepared by adding a chelating agent prior to final pH adjustment of the aqueous solution.
- the chelating agent is at least one selected from citric acid, malic acid, ethylenediaminetetraacetic acid, ethylenediaminetetraacetic acid iron (III) sodium salt and sialic acid, and salts or hydrates thereof.
- Method. 18 18.
- the powder medium is a powder further containing at least one selected from metal salts, sugars and vitamins.
- 20. The method for membrane filtration as described in 18 or 19 above, wherein the medium is a cell culture medium. 21. 21. The method of membrane filtration as described in 20 above, wherein the medium is a medium for animal cell culture. 22. 22. The method for membrane filtration according to 21 above, wherein the medium is a medium for CHO cell culture derived from Chinese hamster ovary tissue. 23. 23.
- a method for improving the membrane filterability of an aqueous solution comprising adding a chelating agent to an aqueous solution to prepare an aqueous solution containing the chelating agent and subjecting the aqueous solution to membrane filtration. 25. 25. A method for improving the membrane filterability of an aqueous solution as described in 24 above, further comprising adding an aqueous medium to the aqueous solution to prepare an aqueous solution containing the medium and a chelating agent, and subjecting the aqueous solution to membrane filtration. 26. 26.
- the present inventors have found for the first time that the membrane filterability of the aqueous solution is greatly improved by adding a chelating agent in the aqueous solution preparation method. Further, the present inventors have found that the membrane filterability is improved depending on the addition concentration of the chelating agent in the aqueous solution preparation method.
- the present inventors have found that the membrane filterability of the aqueous solution is greatly improved by adding the chelating agent prior to the final pH adjustment of the aqueous solution in the aqueous solution preparation method.
- the present inventors have found that a physiologically active substance can be produced by culturing cells using an aqueous solution prepared by adding a chelating agent prior to final pH adjustment of the aqueous solution.
- a method for preparing an aqueous solution containing a medium and a chelating agent can be provided. Further, using an aqueous solution prepared by the method, a cell culturing method using the aqueous solution prepared by the method, a method for producing a physiologically active substance using the cell culturing method, and a method for producing the physiologically active substance It has been shown that the bioactive substances produced can be provided.
- a method for membrane filtration of an aqueous solution prepared by the method for preparing the aqueous solution and a method for improving membrane filtration properties characterized by preparing an aqueous solution using a chelating agent can be provided. It was also shown that a method for producing a physiologically active substance can be provided by subjecting an aqueous solution prepared by the preparation method to membrane filtration and then culturing cells using the obtained aqueous solution.
- FIG. 1 shows that the filterability of an aqueous solution is improved by adding a chelating agent.
- the vertical axis indicates the maximum throughput [Vmax (L / m 2 )] per unit membrane area.
- the horizontal axis shows the chelating agent used.
- FIG. 2 shows that the filterability of the aqueous solution is significantly improved by adding the chelating agent prior to the final pH adjustment of the aqueous solution.
- the vertical axis indicates the maximum throughput [Vmax (L / m 2 )] per unit membrane area.
- the horizontal axis indicates the time when the chelating agent is added.
- FIG. 3 shows that the filterability is improved depending on the concentration of the chelating agent.
- the vertical axis indicates the maximum throughput [Vmax (L / m 2 )] per unit membrane area.
- the horizontal axis represents the chelating agent concentration (g / L).
- FIG. 4 shows that the filterability improving effect by the chelating agent does not depend on the membrane material and the membrane structure.
- the vertical axis indicates the maximum throughput [Vmax (L / m 2 )] per unit membrane area.
- the horizontal axis indicates the material of the filtration membrane.
- FIG. 5 shows that the filterability of the aqueous solution is significantly improved by adding sialic acid as a chelating agent.
- the vertical axis indicates the maximum throughput [Vmax (L / m 2 )] per unit membrane area.
- the horizontal axis indicates the type of solution.
- the present invention relates to a method for preparing an aqueous solution containing a medium and a chelating agent, wherein the chelating agent is added to the aqueous solution prior to final pH adjustment of the aqueous solution.
- the aqueous solution is not particularly limited, but preferably includes an aqueous solution capable of culturing cells and the like (also referred to as an aqueous solution for cell culture).
- Examples of the medium include a powder medium, a liquid medium, and a slurry medium. These media can be appropriately selected from commercially available media, and two or more types of media may be mixed. Furthermore, known media described in literatures can be selected.
- the medium examples include a medium for bacterial cell culture, a medium for yeast cell culture, a medium for plant cell culture, a medium for animal cell culture, and the like. Among these, a medium for animal cell culture is preferable.
- the medium is not particularly limited, and examples thereof include an expansion culture medium, a basic (initial) medium, and a feed medium.
- the medium may be any of a synthetic medium, a semi-synthetic medium, or a natural medium.
- examples thereof include a basal medium, a serum-containing medium, a serum-free medium, a medium not containing animal-derived components, or a protein-free medium.
- a serum-free medium, a protein-free medium, or a completely synthetic medium is preferable.
- a medium for cell culture a medium for animal cell culture is preferable, and a medium for CHO cell culture derived from Chinese hamster ovary tissue is more preferable.
- basal medium for example, RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Dulbecco's modified MEM (DMEM) medium [DMEM] medium [DMEM] medium, for example. , 8, 396 (1959)], 199 medium [Proceeding of the Society for the Biological Medical, 73, 1 (1950)], F12 medium (manufactured by LTI) [Proc. Natl. Acad. Sci. USA, 53, 288 (1965)], Iskov modified Dulbecco medium (IMDM medium) [J.
- EX-CELL registered trademark
- EX-CELL registered trademark
- EX-CELL registered trademark
- 325 manufactured by SAFC Bioscience
- CHO-S-SFMII manufactured by Invitrogen
- RPMI1640 medium DMEM medium
- F12 medium IMDM
- EX-CELL registered trademark
- hybridoma SFM medium Invitrogen
- the serum-containing medium examples include a basal medium, mammalian serum such as cow or horse, avian animal serum such as chicken, fish animal serum such as yellowtail, or one or more kinds of serum from the above serum fractions. Or what added the serum fraction is mentioned.
- serum-free medium examples include a basal medium supplemented with nutrient factors or physiologically active substances that are serum substitutes.
- substances that are added instead of animal-derived components may be added.
- the substance include physiologically active substances produced by genetic recombination methods, hydrolysates, and lipids that do not contain animal-derived materials.
- the protein-free medium includes, for example, an ADPF medium (Animal derived protein free medium, manufactured by High Clone), CD-Hybridoma medium (manufactured by Invitrogen), CD-CHO medium (manufactured by Invitrogen), IS-CD-CHO medium ( Irvine Scientific) or EX-CELL (registered trademark) CD-CHO medium (SAFC Bioscience).
- ADPF medium Animal derived protein free medium, manufactured by High Clone
- CD-Hybridoma medium manufactured by Invitrogen
- CD-CHO medium manufactured by Invitrogen
- IS-CD-CHO medium Irvine Scientific
- EX-CELL registered trademark
- the production method of the powder medium is not particularly limited, but preferably, a production method by a mixing process such as a disk mill, a ball mill or a pin mill of a dry component, or a production method by freeze-drying an aqueous solution prepared in advance, etc. It is done.
- the powder medium includes a medium that exists in the form of granules.
- the finely divided component may further include a step of spraying and drying a solution in which at least one material selected from the group consisting of natural glues, synthetic glues, sugars, and fats and oils is dissolved. Good.
- the desired nutrient factor can be appropriately selected and added to the medium.
- you may comprise a culture medium with the component which selected the desired trophic factor suitably.
- the nutrition factor include a carbon source such as a saccharide or a nitrogen source such as an amino acid.
- Specific examples include amino acids, metals, vitamins, sugars, salts, lipids, nucleic acids, physiologically active substances, fatty acids, organic acids, proteins, hydrolysates, and the like.
- these compounds may form salts such as hydrochloride, sodium salt, potassium salt, ammonium salt, and / or solvates such as hydrates.
- the amino acid is not particularly limited.
- L-alanine (Ala), L-arginine (Arg), L-asparagine (Asn), L-aspartic acid (Asp), L-cysteine (Cys), L-cystine L-glutamic acid (Glu), L-glutamine (Gln), glycine (Gly), L-histidine (His), L-isoleucine (Ile), L-leucine (Leu), L-lysine (Lys), L-methionine (Met), L-phenylalanine (Phe), L-proline (Pro), L-serine (Ser), L-threonine (Thr), L-tryptophan (Trp), L-valine (Val), etc.
- salts such as hydrochlorides and sodium salts and / or solvates such as hydrates may be used. It may be added as a peptide, and examples thereof include L-alanyl-L-glutamine or L-alanyl-L-cysteine.
- physiologically active substance examples include insulin, transferrin, serum albumin or a serum fraction containing a growth factor.
- lipids examples include cholesterol, linoleic acid, and linolenic acid.
- salts such as hydrochlorides and sodium salts and / or solvates such as hydrates may be used.
- metal For example, iron, manganese, zinc, molybdenum, vanadium, copper, cadmium, rubidium, cobalt, zirconium, germanium, nickel, tin, chromium, silicon etc. are mentioned, 1 type or 2 types or more Used in combination. These metals may form, for example, salts such as hydrochloride, sulfate, sodium salt, potassium salt and ammonium salt, and / or solvates such as hydrate.
- the saccharide may be any of monosaccharide, oligosaccharide and polysaccharide, and is not particularly limited.
- sugar derivatives such as deoxy sugar, uronic acid, amino sugar or sugar alcohol are also included.
- glucose, mannose, galactose, fructose, ribose, arabinose, ribulose, erythrose, erythrulose, glyceraldehyde, dihydroxyacetone, sedoheptulose, maltose, lactose or sucrose can be used, and one or more can be used in combination.
- salts such as hydrochlorides and sodium salts and / or solvates such as hydrates may be used.
- the vitamin is not particularly limited, and examples thereof include d-biotin, D-pantothenic acid, choline, folic acid, myo-inositol, niacinamide, pyridoxal, riboflavin, thiamine, cyanocobalamin, and DL- ⁇ -tocopherol. Or two or more types are used in combination. Further, salts such as hydrochlorides and sodium salts and / or solvates such as hydrates may be used.
- hydrolyzate examples include hydrolysates such as soybean, wheat, rice, peas, cottonseed, fish or yeast extract, or extracts.
- hydrolysates such as soybean, wheat, rice, peas, cottonseed, fish or yeast extract, or extracts.
- SOY HYDROLYSATE UF manufactured by SAFC Bioscience, catalog number: 91052-1K3986, or 91052-5K3986
- the chelating agent is not particularly limited as long as it is suitable for the purpose of use of the aqueous solution prepared by adding the chelating agent.
- the chelating agent of the present invention one type or a plurality of types of chelating agents may be used.
- a water-soluble chelating agent is particularly preferable, and examples thereof include aminocarboxylic acid type, oxycarboxylic acid type, lower dibasic carboxylic acid type, polyhydric alcohol, and inorganic compound type.
- the chelating agent of the present invention may form a salt or the like as long as the chelating effect is maintained, for example, a salt such as hydrochloride, sodium salt, potassium salt, ammonium salt, and / or hydration A solvate such as a product may be formed.
- aminocarboxylic acid-based chelating agents include nitrilotriacetic acid (NTA), N-hydroxyethyliminodiacetic acid (NIMDA), ethylenediaminediacetic acid (EDDA), ethylenediaminetetraacetic acid (EDTA), and ethylenediamine.
- Tetraacetic acid iron (III) sodium salt (EDTA iron (III) sodium salt), N-hydroxyethylethylenediaminetetraacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), 1,2-cyclohexanediaminetetraacetic acid (CyDTA), trimethylene Diamine tetraacetic acid (TMTA), ethylene glycol diethyl ether diamine tetraacetic acid (GEDTA), ethylenediaminetetrapropionic acid (EDTP), glutamic acid-N, N-diacetic acid, aspartic acid-N, N- Acid, glycine, alanine, solvate, etc. These salts and / or hydrates thereof.
- oxycarboxylic acid-based chelating agents include, for example, lactic acid, glycolic acid, citric acid, malic acid, tartaric acid, gluconic acid, mandelic acid, solvates of these salts and / or hydrates, and the like. Is mentioned.
- the lower dibasic carboxylic acid-based chelating agent include oxalic acid, malonic acid, solvates of these salts and / or hydrates, and the like.
- polyhydric alcohol examples include glycols such as ethylene glycol, diethylene glycol and triethylene glycol, and sugar alcohols. Specific examples include inositol and the like such as glycerin, erythrite, arabit, xylit, sorbit, mannitol or galactite.
- the inorganic compound-based chelating agent examples include pyrophosphoric acid, triphosphoric acid, condensed phosphoric acid, solvates of these salts and / or hydrates, and the like. Particularly preferred as a chelating agent is trisodium citrate dihydrate, L-malic acid or ethylenediaminetetraacetic acid iron (III) sodium salt.
- sialic acid can be used as a chelating agent.
- Sialic acid means 2-keto-3 deoxynonic acid having a carboxyl group consisting of nine carbon skeletons, and is also called neuraminic acid.
- Sialic acid includes N-acetylneuraminic acid, N-glycolylneuraminic acid, O-acetylneuraminic acid, or deaminoneuraminic acid, or salts, hydrates and / or derivatives thereof, etc. It is.
- sialic acid includes those having 5-N-acetyl or 5-N-glycolylneuraminic acid as a skeleton, wherein some of the hydroxyl groups are O-acetylated.
- the sialic acid of the present invention is particularly preferably N-acetylneuraminic acid dihydrate.
- the chelating agent can be produced by a known chemical synthesis method.
- the chelating agent is added during preparation of the aqueous solution, and it is particularly preferable to add the chelating agent to the aqueous solution prior to final pH adjustment.
- the order in which the chelating agents are added to the aqueous solution can be appropriately selected depending on the composition of the medium to be added, the type of the chelating agent, etc., as long as it is prior to the final pH adjustment of the aqueous solution. .
- the membrane filterability of the prepared aqueous solution can be improved.
- the chelating agent can be added to the aqueous solution simultaneously with or before any medium, and is preferably added to the aqueous solution before or simultaneously with the medium. Further, the chelating agent can be added to the medium in advance. By adding the chelating agent to the aqueous solution prior to or simultaneously with the medium, the membrane filterability of the prepared aqueous solution can be further improved.
- the final pH adjustment in the present invention refers to a step of adjusting the pH of the aqueous solution to a predetermined pH.
- the final pH is adjusted according to the intended use of the aqueous solution.
- the pH value may be any value as long as cells can be cultured.
- pH adjustment is unnecessary, the final addition of the substance contained in the aqueous solution to the aqueous solution is regarded as the final pH adjustment.
- the final pH adjustment can be performed using any acid or alkali. Specifically, for example, sodium bicarbonate, hydrochloric acid, sodium hydroxide and the like can be used.
- Na 2 CO 3 or 4- (2-hydroxyethyl) -1-piperazine ethersulfonic acid (which adjusts the pH in the medium) HEPES), 3- (N-Morpholino) propanesulphonic acid (MOPS), etc. may already be contained.
- the amount of the chelating agent added is not particularly limited, but after the aqueous solution is prepared, the concentration of the added chelate in the aqueous solution is preferably 0.001 mmol / L or more, more preferably 0.01 mmol / L or more, and still more preferably 0. It is preferable to add an amount such that it is 1 mmol / L or more, particularly preferably 0.34 mmol / L or more.
- the amount of the chelating agent added to the aqueous solution is within the range of 0.001 to 1000 mmol / L, 0.01 to 100 mmol / L, 0.1 to 100 mmol / L, 0.1 to 50 mmol / L, and the like. However, it is preferable to add an amount such that it is 0.34 to 89 mmol / L, more preferably 0.34 to 15 mmol / L, and particularly preferably 0.34 to 6.8 mmol / L. You can also.
- the concentration of the chelating agent in the prepared aqueous solution may be higher due to the metal such as iron and the chelate complex added as a source of metal such as iron in the medium.
- hydrolyzate, metal salt, saccharide, vitamin, amino acid, pH adjuster, organic acid, fatty acid, peptide, physiologically active substance, lipid or nucleic acid, etc. are separately or partially mixed in a medium. It can also be added. Metal salts, sugars or vitamins can also be added to the culture medium.
- the cells may be eukaryotic cells or prokaryotic cells, for example, cells derived from mammals, birds, reptiles, amphibians, fish, insects or plants, microorganisms such as bacteria, Escherichia coli or Bacillus subtilis, bacteria, Escherichia coli or Examples include cells derived from microorganisms such as Bacillus subtilis, yeasts, or cells derived from yeasts.
- animal cells belonging to mammals are preferred, animal cells derived from primates such as humans or monkeys or animal cells derived from rodents such as mice, rats or hamsters, more preferably derived from Chinese hamster ovary tissue. CHO cells are most preferred.
- CHO cells derived from Chinese hamster ovary tissue in the present invention include any cells established from ovarian tissue of Chinese hamster (Crichetulus griseus).
- CHO-K1 strain ATCC No. CCL-61
- DUXB11 strain ATCC CRL-9096
- Pro-5 strain ATCC CRL-1781 registered in ATCC (The American Type Culture Collection)
- CHO / dhfr- ATCC No. CRL-9096
- commercially available CHO-S strain Lifetechnologies Cat # 11619
- CHO / DG44 Proc. Natl. Acad. Sci. USA, 77, 4216 (1980)] or sub-strains obtained by acclimating these strains to various media.
- Examples of cells belonging to mammals include myeloma cells, ovarian cells, kidney cells, blood cells, uterine cell connective tissue cells, mammary gland cells or embryonic retinoblasts, or cells derived from these cells.
- myeloma cells cells derived from myeloma cells, ovary cells, or cells derived from ovarian cells are preferable.
- human cell lines HL-60 ATCC No. CCL-240
- HT-1080 ATCC No. CCL-121
- HeLa ATCC No. CCL-2
- 293 ECACC No. 85120602
- Namalwa ATCC CRL-1432
- Namalwa KJM-1 Chinese Cell ACC2605, International Publication No. 2005/017130
- PER. C6 ECACC No. 96022940, US Pat. No. 6,855,544
- VERO ATCC No. CCL-1651
- COS-7 ATCC No. CRL-1651
- monkey cell lines ATCC No. C127I (mouse cell line) ATCC No.
- CRL-1616 Sp2 / 0-Ag14 (ATCC No. CRL-1581), NIH3T3 (ATCC No. CRL-1658), NS0 (ATCC No. CRL-1827), rat cell line Y3 Ag1.
- 2.3. ATCC No. CRL-1631
- YO ECACC No. 85110501
- YB2 / 0 ATCC No. CRL-1662
- Examples of cells belonging to birds include the chicken cell line SL-29 (ATCC No. CRL-29).
- Examples of cells belonging to fish include zebrafish cell line ZF4 (ATCC No. CRL-2050).
- Examples of cells belonging to insects include the Spodoptera frugiperda cell line Sf9 (ATCC No. CRL-1711).
- Examples of primary cultured cells used for vaccine production include primary monkey kidney cells, primary rabbit kidney cells, primary chicken embryo cells, or primary quail embryo cells.
- myeloma cells or cells derived from myeloma cells include Sp2 / 0-Ag14, NS0, Y3, Ag1.2.3. , YO, YB2 / 0, and the like.
- ovary cells or cells derived from ovarian cells include the above-described CHO cells derived from Chinese hamster ovary tissue.
- kidney cells include 293, VERO, COS-7, BHK21, and MDCK.
- Examples of blood cells include HL-60, Namalwa, Namalwa KJM-1, or NM-F9.
- Examples of uterine cells include HeLa.
- Examples of connective tissue cells include HT-1080 and NIH3T3.
- Examples of mammary gland cells include C1271I.
- Examples of embryonic retinoblast cells include PER. C6 etc. are mentioned, respectively.
- the presence or absence of the ability to produce a substance is not particularly limited as a cell.
- iPS cells obtained by introducing several types of genes into somatic cells, sperm and egg cells collected from mammalian donors including humans Examples thereof include cells that produce a substance or fused cells that have produced a substance.
- cells that produce substances, or fused cells that have produced substances are preferable, such as animal cells that produce substances, or fusion cells derived from animals that have produced substances. More preferred.
- the desired substance is an antibody
- a hybridoma that is a fusion cell of an antibody-producing cell such as a B cell and a myeloma cell can be used.
- Animal cells that have been subjected to mutation treatment to produce substances, or animal cells that have been subjected to mutation treatment to increase the expression level of substances are also included in animal cells.
- animal cells that have been subjected to mutation treatment to produce substances include cells in which mutations have been introduced into protein modifying enzymes, etc. in order to be able to produce desired substances.
- the desired substance is a glycoprotein
- cells in which mutations are introduced into various sugar chain modifying enzymes in order to change the structure of the sugar chain can be mentioned.
- any animal cell may be used as the animal cell that produces the substance as long as the desired substance can be produced.
- an animal cell transformed with a recombinant vector containing a gene involved in the production of the substance are also included.
- the transformed cell can be obtained by introducing a DNA involved in the production of a substance and a recombinant vector containing a promoter into the cells belonging to the mammal.
- DNA encoding a substance such as a peptide DNA encoding an enzyme or protein involved in the biosynthesis of the substance, and the like can be used.
- Any promoter can be used as long as it functions in the animal cells used in the present invention.
- a cytomegalovirus (CMV) immediate early (IE) gene promoter for example, a cytomegalovirus (CMV) immediate early (IE) gene promoter, an SV40 early promoter, a retrovirus Promoter, metallothionein promoter, heat shock promoter, SR ⁇ promoter and the like.
- an enhancer of IE gene of human CMV may be used together with a promoter.
- Recombinant vectors can be prepared using desired vectors. Any vector can be used as the vector used for preparing the recombinant vector as long as it functions in the animal cells used in the present invention.
- Any vector can be used as the vector used for preparing the recombinant vector as long as it functions in the animal cells used in the present invention.
- pcDNAI, pcDM8 manufactured by Funakoshi
- pAGE107 [Japan KOKAI Publication No. 3-22979, Cytotechnology, 3, 133 (1990)]
- pAS3-3 Japanese Unexamined Patent Publication No. 227075
- pcDM8 [Nature, 329, 840 (1987)]
- pcDNAI / Amp Invitrogen
- pREP4 Invitrogen
- pAGE103 [J. Biochem. , 101, 1307 (1987)]
- pAGE210 and the like.
- any method for introducing a recombinant vector into a host cell any method can be used as long as it is a method for introducing DNA into the cell.
- electroporation [Cytotechnology, 3, 133 (1990)]
- calcium phosphate Method Japanese Patent Laid-Open No. 2-227075
- lipofection method Proc. Natl. Acad. Sci. USA, 84, 7413 (1987), Virology, 52, 456 (1973)] and the like.
- transformed cells include transformed cells 7-9-51 (FERM BP-6691) that produce anti-GD3 human chimeric antibodies and transformed cells KM2760 (FERM) that produce anti-CCR4 chimeric antibodies.
- BP-7054 transformed cells KM8759 (FERM BP-8129) and KM8760 (FERM BP-8130), 709LCA-500D (FERM BP-8239), anti-IL-5 receptor ⁇ chain producing anti-CCR4 humanized antibody Transformed cells producing chimeric antibodies KM7399 (FERM BP-5649), transformed cells producing anti-IL-5 receptor ⁇ chain human CDR-grafted antibodies KM8399 (FERM BP-5648) and KM9399 (FERM BP-5647) Anti-GM2 human CDR-grafted antibody Transformed cells to be produced KM8966 (FERM BP-5105), KM8967 (FERM BP-5106), KM8969 (FERM BP-5527), KM8970 (FERM BP-5528), transformed
- the present invention relates to an aqueous solution prepared by a method for preparing an aqueous solution containing a medium and a chelating agent, wherein the chelating agent is added prior to final pH adjustment of the aqueous solution.
- the present invention also relates to a method for culturing cells using an aqueous solution prepared by a method for preparing an aqueous solution containing a medium and a chelating agent, wherein the chelating agent is added prior to the final pH adjustment of the aqueous solution. .
- Examples of the method for culturing cells include batch culture, repeat batch culture, fed-batch culture, and perfusion culture.
- the method for culturing the cells may be any method suitable for the cells used, but fed-batch culture is preferred.
- the culture is usually performed under conditions of pH 6 to 8, 30 to 40 ° C., for example, for 3 to 20 days for fed batch culture and for 3 to 60 days for perfusion culture.
- antibiotics such as streptomycin or penicillin
- the method for storing the aqueous solution is not particularly limited as long as the aqueous solution is maintained in a sterile state, and examples thereof include a method using a stainless tank or a disposable bag.
- the culture method can be used for culturing jars or the like using a very small amount of culture, usually 0.1 mL to 10 mL using a cell culture plate, or a small amount of culture usually 10 to 1000 mL using an Erlenmeyer flask or the like.
- a large amount of culture that can be used for commercial production of usually 1 to 20000 L using a tank or the like may be used.
- the present invention also relates to a method for producing a physiologically active substance, comprising culturing cells using an aqueous solution containing a medium and a chelating agent prepared by adding a chelating agent prior to final pH adjustment of the aqueous solution.
- physiologically active substance produced by the method for producing a physiologically active substance of the present invention is a peptide or protein
- a direct expression method for producing the peptide or protein in the host cell, or a method for secreting and producing the peptide or protein outside the host cell Molecular Cloning 2nd Edition or the like can be used.
- Peptide or protein is prepared by the method of Paulson et al. [J. Biol. Chem. , 264, 17619 (1989)], the method of Lowe et al. [Proc. Natl. Acad. Sci. USA, 86, 8227 (1989), Genes Develop. , 4, 1288 (1990)], or Japanese Patent Application Laid-Open No. 5-336963, International Publication No. 94/23021, and the like, can be actively secreted outside the host cell. . That is, a desired peptide or protein can be actively secreted out of the host cell by expressing the signal peptide bound to the N-terminus of the desired peptide or protein using a genetic recombination technique. I can do it.
- the production amount of a desired peptide or protein can be increased.
- the desired peptide or protein produced by the method of the present invention can be isolated and purified using, for example, a normal peptide or protein isolation and purification method.
- the cells are collected by centrifugation after culturing, suspended in an aqueous buffer, and then subjected to an ultrasonic crusher, French press, Manton Gaurin homogenizer or Cells are disrupted with dynomill or the like to obtain a cell-free extract.
- a normal peptide or protein isolation and purification method that is, a solvent extraction method, a salting-out method using ammonium sulfate, a desalting method, a precipitation method using an organic solvent ,
- Anion exchange chromatography using a resin such as diethylaminoethyl-sepharose, DIAION HPA-75 (manufactured by Mitsubishi Kasei), and a cation exchange chromatography using a resin such as S-sepharose FF (manufactured by Pharmacia)
- Hydrophobic chromatography using resins such as butyl sepharose and phenyl sepharose, gel filtration using molecular sieves, affinity chromatography using resins containing protein A or protein G, chromatofocusing, or isoelectric
- There is a single electrophoresis method such as point electrophoresis. Is by using a combination, it is possible to obtain
- the peptide or protein can be recovered in the culture supernatant. That is, a culture supernatant is obtained by treating the culture by a method such as centrifugation as described above, and a crudely purified sample is obtained from the culture supernatant by using the same isolation and purification method as described above. Alternatively, a purified sample can be obtained.
- the physiologically active substance may be any substance that can produce cells, preferably animal cells, but is preferably a substance that can produce animal cells belonging to mammals.
- Such substances include, for example, biocatalytic molecules such as amino acids, peptides, proteins or ribozymes, formation / retention molecules such as keratin, collagen, elastin, resilin or fibroin, pressure ulcer vaccine, polio vaccine, measles vaccine, rubella vaccine, Mumps vaccine, rabies vaccine, varicella vaccine, bovine epidemic fever vaccine, Ibaraki disease vaccine or bovine infectious tracheitis vaccine, or a virus such as adenovirus or baculovirus.
- the peptide is preferably a eukaryotic cell-derived peptide, more preferably an animal cell-derived peptide, for example, a mammalian cell-derived peptide.
- the peptide includes a desired peptide and may have any shape as long as it has activity, for example, an artificially modified peptide such as a fusion peptide fused with another peptide. Alternatively, it may be a peptide consisting of a partial fragment.
- peptides examples include peptides that maintain the activity of the glycoprotein among the partial fragments of the glycoprotein.
- a peptide that regulates the activity of the enzyme or a peptide that retains the structure of the enzyme is also included.
- Specific examples of peptides that regulate enzyme activity include peptides that function as glycoprotein agonists or antagonists.
- the agonist may be any peptide as long as it has an activity to enhance the activity of glycoprotein.
- somatostatin derivative for example, somatrobin, atrial natriuretic peptide, glucagon, insulin, insulin-like growth factor or Examples include gonadotropins.
- the antagonist may be any peptide as long as it has an activity of suppressing glycoprotein activity, and specifically includes, for example, pegvisomaton.
- the protein is preferably a protein derived from a eukaryotic cell, more preferably a protein derived from an animal cell, and examples thereof include a protein derived from a mammalian cell.
- the protein may be any structure as long as it contains the desired protein and has activity, for example, an artificially modified protein such as a fusion protein fused with another protein. It may be a protein consisting of partial fragments.
- proteins include glycoproteins and antibodies.
- glycoproteins include erythropoietin (EPO) [J. Biol. Chem. , 252, 5558 (1977)], thrombopoietin (TPO) [Nature, 369 533 (1994)], tissue type plasminogen activator, prourokinase, thrombomodulin, antithrombin III, protein C, protein S, blood coagulation factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XI, blood clotting factor XII, prothrombin complex, fibrinogen, albumin, gonadotropin, thyroid stimulating hormone, epidermal growth factor (EGF), Hepatocyte growth factor (HGF), keratinocyte growth factor, activin, osteogenic factor, stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF) [J.
- EPO erythropoietin
- TPO thrombopoietin
- Macrophage colony-stimulating factor [J. Exp. Med. , 173, 269 (1992)] granulocyte-macrophage colony stimulating factor (GM-CSF) [J. Biol. Chem. , 252, 1998 (1977)], interferon ⁇ , interferon ⁇ , interferon ⁇ , interleukin-2 (IL-2) [Science, 193, 1007 (1976)], interleukin 6, interleukin 10, interleukin 11, Interleukin-12 (IL-12) [J. Leuc. Biol.
- the antibody may be any antibody having antigen-binding properties, such as an antibody recognizing a tumor-related antigen or an antibody fragment thereof, an antibody recognizing an antigen associated with allergy or inflammation, or an antibody fragment thereof, and a circulatory organ.
- An antibody that recognizes an antigen related to a disease or an antibody fragment thereof, an antibody that recognizes an antigen related to an autoimmune disease or an antibody fragment thereof, an antibody that recognizes an antigen related to a virus or bacterial infection, or an antibody fragment thereof It is done.
- tumor-associated antigens examples include CD1a, CD2, CD3, CD4, CD5, CD6, CD7, CD9, CD10, CD13, CD19, CD20, CD21, CD22, CD25, CD28, CD30, CD32, CD33, CD38, CD40, CD40Ligand (CD40L), CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD56, CD59, CD63, CD64, CD66b, CD69, CD70, CD74, CD80, CD89, CD95, CD98, CD105, CD134, CD137, CD138 , CD147, CD158, CD160, CD162, CD164, CD200, CD227, adrenomedullin, angiopoietin related pro ein 4 (ARP4), aurora, B7-H1, B7-DC, integlin, bone marlow stromal antigen 2 (BST2), CA125, CA19.9, carbonic anhydrase 9 (CA9), cadherincecre
- G-CSF receptor ganglioside (eg GD2, GD3, GM2 or GM3, etc.), globo H, gp75, gp88, GPR-9-6, heparanase I, hepatocyte growth factor (HGF), HGF, HG -DR etc.), HM1.24, human milk fatglobule (HMFG), hRS7, heat shock protein 90 (hsp90), idiotype epitope factor, insulin-like growth factor (IGF), inter (ILR), ce, etc.
- ganglioside eg GD2, GD3, GM2 or GM3, etc.
- globo H gp75, gp88, GPR-9-6
- heparanase I hepatocyte growth factor
- HGF hepatocyte growth factor
- HGF hepatocyte growth factor
- HG -DR etc. HG -DR etc.
- HM1.24 human milk fatglobule
- hRS7 heat shock protein 90
- IL-6R or IL-15R integrin
- integrin immunoreceptor translocation associated-4
- IRTA-4 immunoreceptor translocation associated-4
- kallikrein 1 KDR
- KIR2DL1 KIR2DL2 / 3, KS1 / 4
- lamp-1 laminin -5
- Lewis y sia ylLewis x
- lymphotoxin-beta receptor LUNX
- MCSP melanoma-associated chondroitin sulfate proteoglycan
- MICA mesothelin
- MICA Mullerian inhibitingsubstance type II receptor
- MIIR melanoma-associated chondroitin sulfate proteoglycan
- mucin neural cell adhesionmolecule
- NCAM neural cell adhesionmolecule
- Necl-5 Notch1
- Osteopontin platelet-derived growth factor
- PDGF platelet-derived growth factor
- PF-4 platelet factor-4
- TRAIL apoptosis-inducingLigand
- TRAIL receptor e.g., such as DR4 or DR5
- ASCT2 system ASC amino acid transporter 2
- trkC trkC
- TROP-2 TWEAK receptor Fn14
- type IV collagenase urokinase receptor
- VEGF vascular endothelialgrowth factor
- VEGF receptor for example, VEGFR1, VEGFR2, or VEGFR3
- vimentin VLA-4, or the like.
- the antibody may be either a monoclonal antibody or a polyclonal antibody.
- Examples of the antibody class include immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin M (IgM), with IgG being preferred.
- IgG1, IgG2, IgG3, or IgG4 is mentioned as a subclass of IgG.
- the antibody includes a fragment containing a part of the antibody.
- Fab Frament of antigen binding
- Fab ′ fragment of antigen binding
- F (ab ′) 2 single chain antibody
- scFv single chain Fv
- disulfide examples thereof include a stabilized antibody (disulphide stabilized Fv, dsFv), a fusion protein containing the Fc region of the antibody, and the like.
- an antibody for example, an antibody produced by gene recombination technology, that is, an antibody expression vector into which an antibody gene is inserted, in addition to an antibody secreted by a hybridoma cell produced from a spleen cell of an animal immunized with an antigen And the like, and the like obtained by introducing into a host cell.
- an antibody for example, an antibody produced by gene recombination technology, that is, an antibody expression vector into which an antibody gene is inserted, in addition to an antibody secreted by a hybridoma cell produced from a spleen cell of an animal immunized with an antigen And the like, and the like obtained by introducing into a host cell.
- Specific examples include antibodies produced by hybridomas, human-type chimerized antibodies, humanized antibodies or human antibodies.
- the human chimeric antibody is a non-human animal antibody heavy chain variable region (hereinafter, the heavy chain is also referred to as H chain, and the variable region is also referred to as HV or VH) and an antibody light chain variable region (hereinafter, light chain).
- LV or VL an L chain
- CH a heavy chain constant region of a human antibody
- CL a light chain constant region of a human antibody
- animals other than humans any animals such as mice, rats, hamsters, rabbits and the like can be used as long as hybridomas can be produced.
- a human chimeric antibody is obtained by obtaining cDNAs encoding VH and VL from a hybridoma producing a monoclonal antibody, and inserting them into expression vectors for host cells having genes encoding human antibody CH and human antibody CL, respectively.
- Type chimeric antibody expression vectors can be constructed and expressed by introducing them into host cells.
- the CH of the human chimeric antibody may be any as long as it belongs to human immunoglobulin (hereinafter referred to as hIg), but is preferably of the hIgG class, and further subclasses of hIgG1, hIgG2, hIgG3 or hIgG4 belonging to the hIgG class. Any of these can be used.
- the CL of the human chimeric antibody may be any as long as it belongs to hIg, and those of ⁇ class or ⁇ class can be used.
- a humanized antibody for example, the amino acid sequence of the VH and VL human type homology determining regions (hereinafter referred to as CDRs) of an antibody of a non-human animal is placed at an appropriate position of the VH and VL of the human antibody.
- CDRs include CDR-grafted antibodies produced by transplantation.
- the CDR-grafted antibody constructs a cDNA encoding the V region in which the CDR sequences of the VH and VL of the non-human animal antibody are grafted onto the CDR sequences of any human antibody, and the human antibody CH and human antibody
- a CDR-grafted antibody expression vector is constructed by inserting each into a host cell expression vector having a gene encoding CL, and the CDR-grafted antibody can be expressed and produced by introducing the expression vector into the host cell. .
- the CH of the CDR-grafted antibody may be any as long as it belongs to hIg, but is preferably of the hIgG class, and any subclass such as hIgG1, hIgG2, hIgG3, or hIgG4 belonging to the hIgG class can be used.
- the CL of the CDR-grafted antibody may be any as long as it belongs to hIg, and those of ⁇ class or ⁇ class can be used.
- the human antibody is, for example, that human lymphocytes can be cultured by isolating and immortalizing and cloning human peripheral blood lymphocytes, and purifying the antibody from the culture. I can do it.
- Human antibodies can be prepared from a human antibody phage library.
- the human antibody phage library is a library in which antibody fragments such as Fab or scFv are expressed on the phage surface by inserting an antibody gene prepared from human B cells into the phage gene. From the library, phages expressing antibody fragments having antigen-binding activity can be recovered using the binding activity to the immobilized antigen as an index.
- the antibody fragment can be converted into a human antibody molecule consisting of two complete H chains and two complete L chains.
- cDNAs encoding VL and VH are obtained from human antibody-producing hybridomas, and one or more amino acid residues of wild type (hereinafter referred to as WT) are appropriately substituted with Cys residues by the above-described method or the like. It can also be produced by inserting it into an expression vector for animal cells having DNA encoding the CL and CH of the human antibody and introducing it into animal cells.
- a human antibody-producing hybridoma can be obtained from a human antibody-producing transgenic animal by a conventional hybridoma production method performed in mammals other than humans.
- a human antibody-producing transgenic animal refers to an animal in which a human antibody gene is incorporated into cells.
- a human antibody-producing transgenic mouse can be produced by introducing a human antibody gene into a mouse ES cell, and transplanting the ES cell into an early embryo of the mouse, followed by generation [Proc. Natl. Acad. Sci. USA, 97, 722 (2000)].
- cDNAs encoding VL and VH are obtained from human antibody-producing hybridomas, and inserted into expression vectors for animal cells having DNAs encoding CL and CH of human antibodies, respectively, and the above-described method as appropriate. It is also possible to construct a human antibody expression vector by substituting one or more amino acid residues of WT with a Cys residue, etc., and introducing the human antibody expression vector into an animal cell for expression.
- WT CH used for human antibodies may be any as long as it belongs to hIg, but is preferably hIgG class, and any of subclasses such as hIgG1, hIgG2, hIgG3, and hIgG4 belonging to hIgG class can be used.
- the CL of the human antibody may be any as long as it belongs to hIg, and those of ⁇ class or ⁇ class can be used.
- antibody produced by the method of the present invention include the following antibodies, but are not particularly limited thereto.
- antibodies that recognize tumor-associated antigens include, for example, anti-GD2 antibody [Anticancer Res. , 13, 331 (1993)], anti-GD3 antibody [Cancer Immunol. Immunother. , 36, 260 (1993)], anti-GM2 antibody [Cancer Res. , 54, 1511 (1994)], anti-HER2 antibody [Proc. Natl. Acad. Sci. USA, 89, 4285 (1992), US5725856], anti-CD52 antibody [Proc. Natl. Acad. Sci. USA, 89, 4285 (1992)], anti-MAGE antibody [British J. et al. Cancer, 83, 493 (2000)], anti-HM1.24 antibody [Molecular Immunol.
- anti-parathyroid hormone related protein (PTHrP) antibody [Cancer, 88, 2909 (2000)], anti-bFGF antibody, anti-FGF-8 antibody [Proc. Natl. Acad. Sci. USA, 86, 9911 (1989)], anti-bFGFR antibody, anti-FGF-8R antibody [J. Biol. Chem. , 265, 16455 (1990)], anti-IGF antibodies [J. Neurosci. Res. , 40, 647 (1995)], anti-IGF-IR antibody [J. Neurosci. Res. , 40, 647 (1995)], anti-PSMA antibody [J. Urology, 160, 2396 (1998)], anti-VEGF antibody [Cancer Res.
- PTHrP anti-parathyroid hormone related protein
- anti-VEGFR antibody [Oncogene, 19, 2138 (2000), WO 96/30046], anti-CD20 antibody [Curr. Opin. Oncol. , 10, 548 (1998), US Pat. No. 5,736,137], anti-CD10 antibody, anti-EGFR antibody (WO96 / 402010), anti-Apo-2R antibody (WO98 / 51793), anti ASCT2 antibody (International Publication No. 2010/008075), anti-CEA antibody [Cancer Res. 55 (23 suppl): 5935 s-5945 s, (1995)], anti-CD38 antibody, anti-CD33 antibody, anti-CD22 antibody, anti-EpCAM antibody or anti-A33 antibody.
- antibodies that recognize antigens associated with allergy or inflammation include, for example, anti-interleukin 6 antibody [Immunol. Rev. , 127, 5 (1992)], anti-interleukin 6 receptor antibody [Molecular Immunol. , 31, 371 (1994)], anti-interleukin-5 antibody [Immunol. Rev. , 127, 5 (1992)], anti-interleukin 5 receptor antibody, anti-interleukin 4 antibody [Cytokine, 3,562 (1991)], anti-interleukin 4 receptor antibody [J. Immunol.
- antibodies that recognize antigens related to cardiovascular diseases include anti-GPIIb / IIIa antibodies [J. Immunol. , 152, 2968 (1994)], anti-platelet-derived growth factor antibody [Science, 253, 1129 (1991)], anti-platelet-derived growth factor receptor antibody [J. Biol. Chem. 272, 17400 (1997)], anticoagulant factor antibody [Circulation, 101, 1158 (2000)], anti-IgE antibody, anti- ⁇ V ⁇ 3 antibody or ⁇ 4 ⁇ 7 antibody.
- antibodies that recognize antigens associated with virus or bacterial infection include anti-gp120 antibody [Structure, 8, 385 (2000)], anti-CD4 antibody [J. Rheumatology, 25, 2065 (1998)], anti-CCR5 antibody or anti-verotoxin antibody [J. Clin. Microbiol. , 37, 396 (1999)].
- the present invention also provides a culture medium characterized by adding a chelating agent prior to the final pH adjustment of the aqueous solution and an aqueous solution prepared by the method for preparing an aqueous solution containing the chelating agent. It relates to the bioactive substance produced.
- the present invention also relates to a method for membrane filtration of an aqueous solution containing a culture medium and a chelating agent, using the aqueous solution prepared by adding a chelating agent prior to final pH adjustment of the aqueous solution.
- the method for membrane filtration is not particularly limited as long as it is a method that allows the treatment aqueous solution to pass through the porous membrane by pressure and removes components, particles, contaminants, etc. in the solution, but is not limited thereto.
- Dialysis, electrodialysis or reverse osmosis is preferred, microfiltration, ultrafiltration or dialysis is more preferred, and microfiltration is particularly preferred.
- the filtration membrane used for membrane filtration is not particularly limited, but is preferably a microfiltration membrane, ultrafiltration membrane, dialysis membrane, electrodialysis membrane or reverse osmosis membrane, more preferably a microfiltration membrane, ultrafiltration membrane or dialysis membrane.
- a microfiltration membrane is particularly preferred.
- the material of the filtration membrane is not particularly limited.
- polyether sulfone or polyvinylidene fluoride is preferable.
- filtration membranes using polyethersulfone or derivatives thereof include, for example, Millipore Express (registered trademark) PLUS Membrane Filters (pore size: 0.22 or 0.45 ⁇ m) (Millipore), Millipore Express SHC cartridge filter (Millipore), Millipore Express SHR cartridge filter (Millipore), Super EBV (Pall), Super EKV (Pall, catalog number: AB3EKV7PH4 PH4) Zaltopore 2 (membrane structure: two-layer membrane, pore size: 0.2 + 0.1, 0.45 + 0.2, or 0.
- a filtration membrane using polyvinylidene fluoride or a derivative thereof specifically, for example, Durapre (registered trademark) Membrane Filters (pore diameter: 0.10, 0.22, 0.45, 0.65, Or 5.0 ⁇ m) (Millipore Inc.), Durapore II Hydrophilic Filter CartridgegV (Millipore Inc.), Durapore II Hydrofiltrate Filter Cartridge VV (registered by Millipore Inc. LP) -DBLP (Pall), Fluorodine II-DJLP (Pall), Ultipore VF-DV20 (Pall) or Ulchi A VF-DV50 (manufactured by Pall Corporation), and the like.
- Durapre registered trademark
- Membrane Filters pore diameter: 0.10, 0.22, 0.45, 0.65, Or 5.0 ⁇ m
- Durapore II Hydrophilic Filter CartridgegV Millipore Inc.
- Durapore II Hydrofiltrate Filter Cartridge VV registered by Millipore
- a filtration membrane combining polyethersulfone or a derivative thereof and polyvinylidene fluoride or a derivative thereof, specifically, for example, Fluorodyne (registered trademark) EXgrade EDF Membrane Filter Cartridge (manufactured by Pall, catalog number: AB3UEDF7PH4) Etc.
- Fluorodyne registered trademark
- EXgrade EDF Membrane Filter Cartridge manufactured by Pall, catalog number: AB3UEDF7PH4
- a filtration membrane using a membrane material other than polyether sulfone or polyvinylidene fluoride specifically, for example, Omnipore (registered trademark) Membrane Filters (pore diameter: 0.1, 0.2, 0.45).
- the pore size of the filtration membrane is not particularly limited, but is preferably 1 nm to 100 ⁇ m, more preferably 5 nm to 10 ⁇ m, still more preferably 10 nm to 1 ⁇ m, and particularly preferably 0.1 ⁇ m to 0.5 ⁇ m.
- Specific examples of the membrane pore diameter include the pore diameters of the filtration membrane examples described above.
- a filtration membrane structure consisting of a single sheet, such as a Millex filter unit (manufactured by Millipore, catalog number: SLGV033RS) may be used.
- 2 ⁇ m Express SHC Disk W / Type (made by Millipore, catalog number: HGEP02550) may be attached to one or more pre-filters to form a structure of two or more layers.
- Vmax (L / m 2 ) is the maximum throughput per unit membrane area obtained after infinite time from the start of filtration, and can be measured by the method described in BioPharm, 46, September (1995).
- the present invention also relates to a method for improving the membrane filterability of an aqueous solution, in which a chelating agent is added to an aqueous solution to prepare an aqueous solution containing the chelating agent, and the aqueous solution is subjected to membrane filtration. Furthermore, the present invention also includes a method for improving the membrane filterability of an aqueous solution, in which an aqueous solution containing a chelating agent and a medium is prepared by adding the chelating agent and the medium to the aqueous solution, and the aqueous solution is subjected to membrane filtration.
- the present invention also provides a medium and an aqueous solution containing the chelating agent by adding a chelating agent to the aqueous solution prior to final pH adjustment of the aqueous solution, and membrane-filtering the aqueous solution, and then using the obtained aqueous solution.
- the present invention relates to a method for producing a physiologically active substance by culturing cells.
- Example 1 Filterability improvement effect by chelating agent The influence on the filterability of the aqueous solution when various chelating agents were added during preparation of the aqueous solution containing the powder medium was examined. Vmax (maximum throughput per unit membrane area) It was clarified that the value of improved.
- the aqueous solution was prepared according to the following procedure. First, in 900 mL of pure water (hereinafter referred to as PW), trisodium citrate dihydrate (manufactured by Kosuge Pharmaceutical Co., Ltd.), L-malic acid (manufactured by Wako, catalog number: 138-07512) as a chelating agent, or Ethylenediaminetetraacetic acid iron (III) sodium salt (hereinafter referred to as EDTA iron (III) sodium salt) (manufactured by Sigma-Aldrich, catalog number: EDFS-100G) was added and stirred. The pH after the chelating agent was completely dissolved was 8.41 for the trisodium citrate dihydrate addition solution, 2.57 for the L-malic acid addition solution, and 5. for the EDTA iron (III) sodium salt addition solution. 11.
- PW pure water
- trisodium citrate dihydrate manufactured by Kosuge Pharmaceutical Co., Ltd.
- L-malic acid manufactured
- SOY HYDROLYSATE UF SAFC Bioscience, catalog number: 91052-1K3986
- improved powder medium EX-CELL 302 SAFC manufactured by Bioscience 22.6 g containing 1 amino acid, metal salt, vitamin and the like and 1 mmol / L methorexate dissolved using PBS (manufactured by Invitrogen, catalog number: 14190-250).
- 0.5 mL of a solution manufactured by Sigma-Aldrich, catalog number: M8407-500MG was added and stirred for about 30 minutes.
- the concentration of each of the added chelating agents described above after preparation of the aqueous solution was 6.8 mmol / L for trisodium citrate dihydrate, 15 mmol / L for L-malic acid, and 5. for EDTA iron (III) sodium salt. 4 mmol / L.
- Vmax test of the prepared aqueous solution was performed according to the following procedure.
- 1 L of the test aqueous solution was placed in a pressurized tank (Millipore).
- Millex (registered trademark) GV Filter Unit manufactured by Millipore, catalog number: SLGV033RS
- the filter was connected to a tank and a pressure of 100 kPa was applied with compressed air.
- the tank valve was slightly opened and the filter was moistened with an aqueous solution. After the filter was wetted, the valve was fully opened to start the test. The time when the valve was fully opened was set to 0, and the elapsed time required to increase the filtration throughput by 5 g was measured. The density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more. A graph was created with the measured value as time (t) on the horizontal axis and t / V on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- Vmax (L / m 2 ) was 452 in the aqueous solution to which no chelating agent was added, whereas 1931, L-apple in the aqueous solution to which trisodium citrate dihydrate was added as the chelating agent. It increased to 2483 in the aqueous solution to which the acid was added and 1834 in the aqueous solution to which the EDTA iron (III) sodium salt was added.
- Vmax value of the aqueous solution is improved by adding a chelating agent during preparation of the aqueous solution.
- Example 2 Trisodium citrate dihydrate addition time and filterability improvement effect The effect of trisodium citrate dihydrate addition time and filterability on the preparation of an aqueous solution containing a powder medium was examined. It is clear that Vmax (maximum throughput per unit membrane area) is greatly increased by adding trisodium citrate dihydrate at the same time or before the powder medium containing amino acids, metal salts, vitamins, etc. I made it. Furthermore, it has been clarified that Vmax (maximum throughput per unit membrane area) is increased by adding trisodium citrate dihydrate before the final pH adjustment step.
- the aqueous solution was prepared according to the following procedure except for the addition of trisodium citrate dihydrate.
- 6.7 g of SOY HYDROLYSATE UF manufactured by SAFC Bioscience, catalog number: 91052-5K3986 was added to 900 mL of pure water (hereinafter referred to as PW) and stirred for about 15 minutes.
- trisodium citrate dihydrate manufactured by Kominato Pharmaceutical Co., Ltd. was added at the time of conditions A to H below to prepare an aqueous solution.
- concentration of trisodium citrate dihydrate added as described above after preparation of the aqueous solution is 0.1 g / L (0.34 mmol / L).
- Condition A No addition Condition B: 10 minutes before the addition of SOY HYDROLYSATE UF Condition C: 1 minute before the addition of SOY HYDROLYSATE UF Condition D: Simultaneous with the addition of SOY HYDROLYSATE UF Condition E: 10 minutes before the addition of improved EX-CELL 302 F: Simultaneous with addition of improved EX-CELL 302 Condition G: 15 minutes before sodium bicarbonate addition Condition H: Immediately after preparation to 1 L with PW
- the Vmax test of the prepared aqueous solution was performed according to the following procedure.
- 1 L of the test aqueous solution was placed in a pressurized tank (Millipore).
- Millex (registered trademark) GV Filter Unit manufactured by Millipore, catalog number: SLGV033RS
- the filter was connected to a tank and a pressure of 100 kPa was applied with compressed air.
- the valve of the tank was slightly opened and the filter was moistened with an aqueous solution. After the filter was wetted, the valve was fully opened to start the test.
- the time when the valve was fully opened was set to 0, and the elapsed time taken to increase the filtration processing amount by 5 g was measured.
- the density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more.
- a graph was created with the measured value as time (t) on the horizontal axis and t / V on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- Vmax (L / m 2 ) was 1163 in condition A, but 3199 in condition B, 3652 in condition C, 3783 in condition D, 3060 in condition E, and 3581 in condition F.
- the filterability of the aqueous solution was greatly improved by adding trisodium citrate dihydrate simultaneously with or before the addition of CELL 302.
- Vmax (L / m 2 ) under condition G is 2502, and the filterability of the aqueous solution can be improved by adding trisodium citrate dihydrate prior to the addition of sodium bicarbonate, which is the pH adjustment step. Improved.
- condition H in which trisodium citrate dihydrate was added after pH adjustment it was 1441, and the improvement of the filterability of the aqueous solution was the same as or slightly increased as A.
- Vmax maximum throughput per unit membrane area
- the Vmax of the aqueous solution increases by adding trisodium citrate dihydrate before the final pH adjustment step. Furthermore, in particular, it was clarified that the Vmax of the aqueous solution is increased by adding trisodium citrate dihydrate to the aqueous solution simultaneously with or before the powder medium containing amino acids, metal salts, vitamins and the like.
- Example 3 Correlation between trisodium citrate dihydrate addition concentration and improvement of aqueous solution filterability Correlation between concentration of trisodium citrate dihydrate added during aqueous solution preparation and filterability was examined, and concentration dependence In particular, it has been clarified that Vmax (maximum throughput per unit film area) is improved.
- the aqueous solution was prepared according to the following procedure. First, 0 g (no addition), 0.1 g, or 1.0 g of trisodium citrate dihydrate (manufactured by Kominato Pharmaceutical Co., Ltd.) was added to 900 mL of pure water (hereinafter referred to as PW) and stirred. After trisodium citrate dihydrate was completely dissolved, 6.7 g of SOY HYDROLYSATE UF (manufactured by SAFC Bioscience, catalog number: 91052-1K3986) was added and stirred for about 15 minutes.
- PW pure water
- the concentration of trisodium citrate dihydrate described above after preparation of the aqueous solution is 0 g / L (no addition), 0.1 g / L (0.34 mmol / L), or 1.0 g / L ( 3.4 mmol / L).
- Vmax test of the prepared aqueous solution was performed according to the following procedure.
- 1 L of the test aqueous solution was placed in a pressurized tank (Millipore).
- Millex (registered trademark) GV Filter Unit manufactured by Millipore, catalog number: SLGV033RS
- the filter was connected to a tank and a pressure of 100 kPa was applied with compressed air.
- the tank valve was slightly opened and the filter was moistened with an aqueous solution. After the filter was wetted, the valve was fully opened to start the test. The time when the valve was fully opened was set to 0, and the elapsed time required to increase the filtration throughput by 5 g was measured. The density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more. A graph was created by taking the measured value as time (t) on the horizontal axis and (t / V) on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- Vmax (L / m 2 ) was 452 in the aqueous solution to which no chelating agent was added, whereas 1706 and 1 in the aqueous solution to which 0.1 g / L of trisodium citrate dihydrate was added.
- the aqueous solution to which 0.0 g / L trisodium citrate dihydrate was added increased to 2588.
- Example 4 Membrane material and membrane structure independence of filterability improvement effect by chelating agent
- the aqueous filterability improvement effect by the chelating agent during preparation of an aqueous solution containing a powder medium was examined using a plurality of filtration membranes.
- a PES having a pore size of 0.2 ⁇ m in which a polyvinylidene fluoride (hereinafter referred to as PVDF) membrane having a pore size of 0.22 ⁇ m or a polyethersulfone (hereinafter referred to as PES) membrane having a pore size of 0.5 ⁇ m as a prefilter is combined.
- PVDF polyvinylidene fluoride
- PES polyethersulfone
- the aqueous solution was prepared according to the following procedure. First, 0 g (no addition) or 0.1 g of trisodium citrate dihydrate (manufactured by Kominato Pharmaceutical) was added to 900 mL of pure water (hereinafter referred to as PW) and stirred. After the trisodium citrate dihydrate was completely dissolved, 6.7 g of SOY HYDROLYSATE UF (manufactured by SAFC Bioscience, catalog number: 91052-1K3986 or 91052-5K3986) was added and stirred for about 15 minutes.
- PW pure water
- improved powder medium EX-CELL 302 (SAFC manufactured by Bioscience) 22.6 g containing 1 amino acid, metal salt, vitamin and the like and 1 mmol / L methorexate dissolved using PBS (manufactured by Invitrogen, catalog number: 14190-250). 0.5 mL of a solution (manufactured by Sigma-Aldrich, catalog number: M8407-500MG) was added and stirred for about 30 minutes. Further, 1.6 g of sodium hydrogen carbonate (manufactured by Kanto Chemical Co., catalog number: 37116-00) was added as a final pH adjustment, and the mixture was stirred for about 5 minutes, then PW was added to 1 L, and the mixture was further stirred for about 10 minutes. The concentration of trisodium citrate dihydrate described above after the aqueous solution preparation is 0 g / L (no addition) or 0.1 g / L (0.34 mmol / L).
- Millex (registered trademark) GV Filter Unit manufactured by Millipore, catalog number: SLGV033RS
- a PVDF membrane having a pore diameter of 0.22 ⁇ m was used as a test filter
- Vmax test of the prepared aqueous solution was performed according to the following procedure. It was. 1 L of the test aqueous solution was placed in a pressurized tank (Millipore). The filter was connected to a tank and a pressure of 100 kPa was applied with compressed air.
- the tank valve was slightly opened and the filter was moistened with an aqueous solution. After the filter was wetted, the valve was fully opened to start the test. The time when the valve was fully opened was set to 0, and the elapsed time required to increase the filtration throughput by 5 g was measured. The density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more. A graph was created with the measured value as time (t) on the horizontal axis and t / V on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- a test filter sufficiently wetted with PW was attached to a folder (Millipore), and the folder was connected to a pressurized tank.
- the valve attached to the folder was opened, and air was fully pushed out from the air vent. After applying a pressure of 120 kPa to the pressurized tank with compressed air, the valve was fully opened to start the test.
- the time when the valve was fully opened was set to 0, and the elapsed time taken to increase the filtration processing amount by 5 g was measured.
- the density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more.
- a graph was created with the measured value as time (t) on the horizontal axis and t / V on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- the filterability of the aqueous solution is improved by adding a chelating agent to the aqueous solution before adjusting the final pH of the aqueous solution even when the material of the filtration membrane to be used is PVDF or PES. Furthermore, even if the structure of the filtration membrane used is a single layer or multiple layers combined with a prefilter, the aqueous solution can be filtered by adding a chelating agent before adjusting the final pH of the aqueous solution. It was clarified that sex improved.
- Example 5 Cultivation of animal cells and production of physiologically active substance using aqueous solution prepared by adding a chelating agent prior to final pH adjustment Trisodium citrate dihydrate prior to final pH adjustment Animal cells were cultured using the prepared aqueous solution. As a result, it was clarified that even in an aqueous solution to which trisodium citrate dihydrate was added, cell growth and titer equivalent to or higher than that of the aqueous solution not added were obtained.
- an improved powder medium EX-CELL 302 (SAFC manufactured by Bioscience) 22.6 g containing amino acids, metal salts, vitamins and the like and 1 mmol / L dissolved using PBS (manufactured by Invitrogen, catalog number: 14190-250) were used. 0.5 mL of a Methotrexate solution (manufactured by Sigma-Aldrich, catalog number: M8407-500MG) was added and stirred for about 30 minutes.
- CHO cells expressing a monoclonal antibody were fed batch cultured in a 3 L reactor for 14 days.
- the seeding density at the initial stage of the culture was about 3.0 ⁇ 10 6 cells / mL, and the temperature of the aqueous solution for culture was controlled to 35 ° C. and the pH to 7.10 during the culture period.
- the aqueous solution for feed includes amino acids [L-alanine, L-arginine monohydrochloride, L-asparagine monohydrate, L-cystine dihydrochloride, L-glutamic acid, L-histidine monohydrochloride dihydrate, L-isoleucine, L-leucine, L-lysine monohydrochloride, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine disodium dihydrate, L-valine (Sigma-Aldrich) L-aspartic acid, glycine (manufactured by Wako Pure Chemical Industries, Ltd.), L-alanyl-L-glutamine (manufactured by Kyowa Hakko Bio), and L-methionine (manufactured by Junsei Kagaku)], vitamin [D- Biotin, calcium D-pantothenate, choline chloride,
- the maximum viable cell density was 5.4 ⁇ 10 6 cells / mL
- the titer of the monoclonal antibody at the end of the culture was 1.
- the maximum cell density reached was 5.8 ⁇ 10 6 cells / mL
- the titer of the monoclonal antibody at the end of the culture was 1.9 g / L.
- Example 6 Filterability improvement effect by addition of N-acetylneuraminic acid dihydrate
- N-acetylneuraminic acid dihydrate was added as a chelating agent when preparing an aqueous solution containing a powder medium, the aqueous solution The influence on the filterability was examined, and it was revealed that the Vmax (maximum throughput per unit membrane area) value of the aqueous solution was improved.
- the aqueous solution was prepared according to the following procedure. First, in 160 mL of pure water (hereinafter abbreviated as PW), 4.0 g of sodium hydroxide (manufactured by Junsei Co., Ltd., catalog number: 39155-0301), L-Tyrosine disodium salt (manufactured by SIGMA, catalog number: T1145-100G) ) 4.5 g, 6.16 g of L-(-)-Cystein Dihydrochlorid (manufactured by Wako Pure Chemicals, catalog number: 034-05322), stirred for about 30 minutes, and then PW was added to make 200 mL of an aqueous solution (hereinafter referred to as the following). (Abbreviated as Cys-Tyr solution).
- powder medium containing amino acids, metal salts, vitamins, etc. in 800 mL of PW, Effective Feed A (Life Technologies, catalog number: A12870SB), 32.6 g, liquid additive, polyamine solution (Life Technologies, catalog number) : A12872SA) 0.5 mL, powder media containing amino acids, metal salts, vitamins, etc.
- Effective Feed B (Life Technologies, catalog number: A11498SA) 27.1 g, L-(+)-glutamine (manufactured by Wako Pure Chemical Industries, Ltd.) Catalog number: 078-00525) 5.0 g, Peptone SE50MAF-UF (manufactured by Wako Pure Chemicals, catalog number: P42474) 30.0 g, D (+)-g 70.0 g of a course (manufactured by Wako Pure Chemical Industries, catalog number: 041-00595) was added, and 30.9 g of N-acetylneuraminic acid dihydrate (manufactured by Kyowa Hakko Bio) was added as a chelating agent. Stir for about 30 minutes.
- the pH after stirring was 4.05. Thereafter, 50 mL of Cys-Tyr solution was added and stirred for about 20 minutes. The pH after adding the Cys-Tyr solution was 4.37. Then, as final pH adjustment, 17 mL of 5 mol / l sodium hydroxide solution (manufactured by Wako Pure Chemical Industries, Catalog No. 196-05375) was added and stirred for about 20 minutes, and then PW was added to 1 L to obtain Solution A. The final pH of solution A was 8.1. The concentration of the above-described added N-acetylneuraminic acid dihydrate after preparation of the aqueous solution is 30.9 g / L (89 mmol / L).
- Vmax test of the prepared aqueous solution was performed according to the following procedure. 1 L of the test aqueous solution was placed in a pressurized tank (Millipore). As a test filter, Millex (registered trademark) GV Filter Unit (manufactured by Millipore, catalog number: SLGV033RS) having a pore diameter of 0.22 ⁇ m was used.
- Millex registered trademark
- GV Filter Unit manufactured by Millipore, catalog number: SLGV033RS
- the filter was connected to the tank and a pressure of 100 kPa was applied with compressed air. Before starting the test, the valve of the tank was slightly opened and the filter was moistened with an aqueous solution. After the filter was wetted, the valve was fully opened to start the test.
- the time when the valve was fully opened was set to 0, and the elapsed time taken to increase the filtration processing amount by 5 g was measured.
- the density of the aqueous solution was set to 1 g / mL, and the amount of filtration (V) was calculated from the measured weight. The measurement was performed for 3 minutes or more.
- a graph was created with the measured value as time (t) on the horizontal axis and t / V on the vertical axis, and Vmax was calculated from the reciprocal of the slope of the obtained straight line.
- Vmax (L / m 2 ) was 190 in solution B to which no chelating agent was added, whereas it was 2025 in solution A to which N-acetylneuraminic acid dihydrate was added as a chelating agent. Increased.
- Vmax of the aqueous solution is improved by adding N-acetylneuraminic acid dihydrate as a chelating agent when preparing an aqueous solution containing a powder medium.
- an aqueous solution preparation method that realizes a dramatic improvement in filterability.
- a highly versatile aqueous solution for cell culture that stably performs membrane filtration in a short time was provided.
- an aqueous solution prepared by the preparation method that achieves dramatic improvement in filterability, a cell culture method using the aqueous solution prepared by the preparation method, a method for producing a physiologically active substance using the culture method, A method for improving the membrane filterability of an aqueous solution, characterized in that a physiologically active substance produced using the production method, a method for membrane filtration of an aqueous solution prepared by the preparation method, and an aqueous solution prepared by adding a chelating agent
- a method for producing a physiologically active substance by preparing an aqueous solution, filtering the membrane, and culturing cells using the aqueous solution was provided.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
1.培地およびキレート剤を含む水溶液の調製方法であって、該水溶液の最終pH調整よりも先にキレート剤を水溶液に添加することを特徴とする、培地およびキレート剤を含む水溶液の調製方法。
2.キレート剤がクエン酸、リンゴ酸、エチレンジアミン四酢酸、エチレンジアミン四酢酸 鉄(III)ナトリウム塩およびシアル酸、並びにそれらの塩または水和物から選ばれる少なくとも1である、前項1に記載の水溶液の調製方法。
3.培地が粉末培地、液体培地またはスラリー状の培地である、前項1または前項2に記載の調製方法。
4.粉末培地がさらに金属塩、糖類およびビタミンから選ばれる少なくとも1を含む培地である、前項3に記載の調製方法。
5.培地が細胞培養用の培地である、前項1~4のいずれか1に記載の調製方法。
6.培地が動物細胞培養用の培地である、前項5に記載の調製方法。
7.培地がチャイニーズハムスター卵巣組織由来のCHO細胞培養用の培地である、前項6に記載の調製方法。
8.前項1~7のいずれか1に記載の方法により調製された、水溶液。
9.前項1~7のいずれか1に記載の方法で調製した水溶液を用いる、細胞の培養方法。
10.細胞が動物細胞である、前項9に記載の細胞の培養方法。
11.細胞がチャイニーズハムスター卵巣組織由来のCHO細胞である、前項10に記載の細胞の培養方法。
12.前項9~11のいずれか1に記載の細胞の培養方法を用いる、生理活性物質の製造方法。
13.生理活性物質がペプチドまたは蛋白質である、前項12に記載の製造方法。
14.蛋白質が糖蛋白質または抗体である、前項13に記載の製造方法。
15.前項12~14のいずれか1に記載の製造方法を用いて製造される、生理活性物質。
16.培地およびキレート剤を含む水溶液を膜ろ過する方法であって、該水溶液が、水溶液の最終pH調整よりも先にキレート剤を添加して調製した水溶液である、膜ろ過する方法。
17.キレート剤がクエン酸、リンゴ酸、エチレンジアミン四酢酸、エチレンジアミン四酢酸 鉄(III)ナトリウム塩およびシアル酸、並びにそれらの塩または水和物から選ばれる少なくとも1である、前項16に記載の膜ろ過する方法。
18.培地が粉末培地、液体培地又はスラリー状の培地である、前項16または前項17に記載の膜ろ過する方法。
19.粉末培地がさらに金属塩、糖類およびビタミンから選ばれる少なくとも1を含む粉末である、前項18に記載の膜ろ過する方法。
20.培地が細胞培養用の培地である、前項18または19に記載の膜ろ過する方法。
21.培地が動物細胞培養用の培地である、前項20に記載の膜ろ過する方法。
22.培地がチャイニーズハムスター卵巣組織由来のCHO細胞培養用の培地である、前項21に記載の膜ろ過する方法。
23.膜ろ過に用いるろ過膜の孔径が1nmから100μmである、前項16~22のいずれか1に記載の膜ろ過する方法。
24.キレート剤を水溶液に添加してキレート剤を含む水溶液を調製し、該水溶液を膜ろ過する、水溶液の膜ろ過性を向上する方法。
25.さらに培地を水溶液に添加して培地およびキレート剤を含む水溶液を調製し、該水溶液を膜ろ過する、前項24に記載の水溶液の膜ろ過性を向上する方法。
26.キレート剤を水溶液の最終pH調整よりも先に水溶液に添加してキレート剤を含む水溶液を調製することを特徴とする、前項24または25に記載の水溶液の膜ろ過性を向上する方法。
27.キレート剤を、培地よりも先または同時に水溶液に添加することを特徴とする、前項24~26のいずれか1に記載の水溶液の膜ろ過性を向上する方法。
28.最終pH調整よりも先にキレート剤を水溶液に添加して培地および該キレート剤を含む水溶液を調製し、該水溶液を膜ろ過した後、得られた水溶液を用いて細胞を培養することによって、生理活性物質を製造する方法。
粉末培地を含む水溶液調製時に各種キレート剤を添加したときの該水溶液のろ過性への影響を検討し、Vmax(単位膜面積あたりの最大処理量)の値が向上することを明らかにした。
粉末培地を含む水溶液調製時における、クエン酸3ナトリウム2水和物の添加時期とろ過性への影響を検討し、クエン酸3ナトリウム2水和物をアミノ酸、金属塩、ビタミン等を含む粉末培地と同時または前に添加することにより、Vmax(単位膜面積あたりの最大処理量)が大幅に増加することを明らかにした。さらに、クエン酸3ナトリウム2水和物を最終pH調整工程より前に添加することにより、Vmax(単位膜面積あたりの最大処理量)が増加することを明らかにした。
条件B:SOY HYDROLYSATE UF添加の10分前
条件C:SOY HYDROLYSATE UF添加の1分前
条件D:SOY HYDROLYSATE UF添加と同時
条件E:改良EX-CELL 302添加の10分前
条件F:改良EX-CELL 302添加と同時
条件G:炭酸水素ナトリウム添加の15分前
条件H:PWで1Lに調製した直後
水溶液調製時に添加するクエン酸3ナトリウム2水和物の濃度とろ過性への相関を検討し、濃度依存的にVmax(単位膜面積あたりの最大処理量)が向上することを明らかにした。
粉末培地を含む水溶液調製時におけるキレート剤による水溶液ろ過性向上効果を、複数のろ過膜を用いて検討した。その結果、孔径0.22μmのポリフッ化ビニリデン(以下、PVDFと称す)膜、または、プレフィルターとして孔径0.5μmのポリエーテルスルフォン(以下、PESと称す)膜を組み合わせた孔径0.2μmのPES膜(以下、孔径0.5/0.2μmのPES膜と称す)において、Vmax(単位膜面積あたりの最大処理量)の値が向上することを明らかにした。
最終pH調整よりも先にクエン酸3ナトリウム2水和物を添加し調製された水溶液を用いて、動物細胞の培養を行った。その結果、クエン酸3ナトリウム2水和物を添加した水溶液においても、添加しなかった水溶液と同等以上の細胞増殖、力価が得られることを明らかにした。
粉末培地を含む水溶液調製時にキレート剤として、N-アセチルノイラミン酸二水和物を添加したときの該水溶液のろ過性への影響を検討し、水溶液のVmax(単位膜面積あたりの最大処理量)値が向上することを明らかにした。
Claims (28)
- 培地およびキレート剤を含む水溶液の調製方法であって、該水溶液の最終pH調整よりも先にキレート剤を水溶液に添加することを特徴とする、培地およびキレート剤を含む水溶液の調製方法。
- キレート剤がクエン酸、リンゴ酸、エチレンジアミン四酢酸、エチレンジアミン四酢酸 鉄(III)ナトリウム塩およびシアル酸、並びにそれらの塩または水和物から選ばれる少なくとも1である、請求項1に記載の水溶液の調製方法。
- 培地が粉末培地、液体培地またはスラリー状の培地である、請求項1または請求項2に記載の調製方法。
- 粉末培地がさらに金属塩、糖類およびビタミンから選ばれる少なくとも1を含む培地である、請求項3に記載の調製方法。
- 培地が細胞培養用の培地である、請求項1~4のいずれか1項に記載の調製方法。
- 培地が動物細胞培養用の培地である、請求項5に記載の調製方法。
- 培地がチャイニーズハムスター卵巣組織由来のCHO細胞培養用の培地である、請求項6に記載の調製方法。
- 請求項1~7のいずれか1項に記載の方法により調製された、水溶液。
- 請求項1~7のいずれか1項に記載の方法で調製した水溶液を用いる、細胞の培養方法。
- 細胞が動物細胞である、請求項9に記載の細胞の培養方法。
- 細胞がチャイニーズハムスター卵巣組織由来のCHO細胞である、請求項10に記載の細胞の培養方法。
- 請求項9~11のいずれか1項に記載の細胞の培養方法を用いる、生理活性物質の製造方法。
- 生理活性物質がペプチドまたは蛋白質である、請求項12に記載の製造方法。
- 蛋白質が糖蛋白質または抗体である、請求項13に記載の製造方法。
- 請求項12~14のいずれか1項に記載の製造方法を用いて製造される、生理活性物質。
- 培地およびキレート剤を含む水溶液を膜ろ過する方法であって、該水溶液が、水溶液の最終pH調整よりも先にキレート剤を添加して調製した水溶液である、膜ろ過する方法。
- キレート剤がクエン酸、リンゴ酸、エチレンジアミン四酢酸、エチレンジアミン四酢酸 鉄(III)ナトリウム塩およびシアル酸、並びにそれらの塩または水和物から選ばれる少なくとも1である、請求項16に記載の膜ろ過する方法。
- 培地が粉末培地、液体培地又はスラリー状の培地である、請求項16または請求項17に記載の膜ろ過する方法。
- 粉末培地がさらに金属塩、糖類およびビタミンから選ばれる少なくとも1を含む粉末である、請求項18に記載の膜ろ過する方法。
- 培地が細胞培養用の培地である、請求項18または19に記載の膜ろ過する方法。
- 培地が動物細胞培養用の培地である、請求項20に記載の膜ろ過する方法。
- 培地がチャイニーズハムスター卵巣組織由来のCHO細胞培養用の培地である、請求項21に記載の膜ろ過する方法。
- 膜ろ過に用いるろ過膜の孔径が1nmから100μmである、請求項16~22のいずれか1項に記載の膜ろ過する方法。
- キレート剤を水溶液に添加してキレート剤を含む水溶液を調製し、該水溶液を膜ろ過する、水溶液の膜ろ過性を向上する方法。
- さらに培地を水溶液に添加して培地およびキレート剤を含む水溶液を調製し、該水溶液を膜ろ過する、請求項24に記載の水溶液の膜ろ過性を向上する方法。
- キレート剤を水溶液の最終pH調整よりも先に水溶液に添加してキレート剤を含む水溶液を調製することを特徴とする、請求項24または25に記載の水溶液の膜ろ過性を向上する方法。
- キレート剤を、培地よりも先または同時に水溶液に添加することを特徴とする、請求項24~26のいずれか1項に記載の水溶液の膜ろ過性を向上する方法。
- 最終pH調整よりも先にキレート剤を水溶液に添加して培地および該キレート剤を含む水溶液を調製し、該水溶液を膜ろ過した後、得られた水溶液を用いて細胞を培養することによって、生理活性物質を製造する方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/976,524 US9611458B2 (en) | 2010-12-27 | 2011-12-27 | Method for preparing aqueous solution containing culture medium and chelating agent |
EP16198419.0A EP3147355B1 (en) | 2010-12-27 | 2011-12-27 | Method for preparing aqueous solution containing culture medium and chelating agent |
EP11854382.6A EP2660315B1 (en) | 2010-12-27 | 2011-12-27 | Method for preparing aqueous solution containing culture medium and chelating agent |
ES11854382T ES2710543T3 (es) | 2010-12-27 | 2011-12-27 | Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante |
JP2012550988A JP5882913B2 (ja) | 2010-12-27 | 2011-12-27 | 培地およびキレート剤を含む水溶液の調製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-290444 | 2010-12-27 | ||
JP2010290444 | 2010-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012091023A1 true WO2012091023A1 (ja) | 2012-07-05 |
Family
ID=46383114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/080236 WO2012091023A1 (ja) | 2010-12-27 | 2011-12-27 | 培地およびキレート剤を含む水溶液の調製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9611458B2 (ja) |
EP (2) | EP2660315B1 (ja) |
JP (1) | JP5882913B2 (ja) |
ES (2) | ES2812923T3 (ja) |
WO (1) | WO2012091023A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020091041A1 (ja) * | 2018-11-02 | 2020-05-07 | 協和キリン株式会社 | 液体培地の調製方法 |
JPWO2019088143A1 (ja) * | 2017-11-01 | 2020-11-12 | 中外製薬株式会社 | 生物活性が低下した抗体バリアントおよびアイソフォーム |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190292514A1 (en) * | 2016-07-14 | 2019-09-26 | Basf Se | Fermentation medium comprising chelating agent |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
JPH07506492A (ja) | 1992-05-09 | 1995-07-20 | ヴエストフアリア ゼパラトール アクチエンゲゼルシヤフト | 無菌培地の連続調合法 |
WO1996030046A1 (en) | 1995-03-30 | 1996-10-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US5725856A (en) | 1988-01-12 | 1998-03-10 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1998051793A1 (en) | 1997-05-15 | 1998-11-19 | Genentech, Inc. | Apo-2 RECEPTOR |
JP2000217455A (ja) | 1999-01-28 | 2000-08-08 | Kubota Corp | イチゴ用液体培地組成物 |
JP2003250533A (ja) | 2002-03-05 | 2003-09-09 | F Hoffmann La Roche Ag | 哺乳類細胞をインビトロで増殖させる改善法 |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
WO2005017130A2 (en) | 2003-08-18 | 2005-02-24 | Glycotope Gmbh | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof |
JP2006500931A (ja) * | 2002-09-30 | 2006-01-12 | ファイザー・プロダクツ・インク | 高レベルのヒト配列抗体を産生するハイブリドーマ |
WO2010008075A1 (ja) | 2008-07-17 | 2010-01-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
WO2010036774A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for purification of viruses |
WO2010036760A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4466889A (en) * | 1981-08-20 | 1984-08-21 | Pfizer Inc. | Polyvalent metal ion chelating agents for xanthan solutions |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US5580348A (en) * | 1994-05-10 | 1996-12-03 | Kimberly-Clark Corporation | Absorbent structure comprising a microbial polysaccharide and a process of making the same |
JP2000517188A (ja) * | 1996-08-30 | 2000-12-26 | ライフ テクノロジーズ,インコーポレイテッド | 無血清哺乳動物細胞培養培地およびその使用 |
AU4751697A (en) * | 1996-10-10 | 1998-05-05 | Douglas Danner | Animal cell culture media comprising plant-derived nutrients |
WO2006050050A2 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
DE102005046225B4 (de) * | 2005-09-28 | 2012-01-05 | Cellca Gmbh | Verbessertes Zellkulturmedium |
US20090298976A1 (en) * | 2005-10-26 | 2009-12-03 | Hiroyuki Yano | Fiber-Reinforced Composition Resin Composition, Adhesive and Sealant |
-
2011
- 2011-12-27 JP JP2012550988A patent/JP5882913B2/ja active Active
- 2011-12-27 ES ES16198419T patent/ES2812923T3/es active Active
- 2011-12-27 ES ES11854382T patent/ES2710543T3/es active Active
- 2011-12-27 WO PCT/JP2011/080236 patent/WO2012091023A1/ja active Application Filing
- 2011-12-27 EP EP11854382.6A patent/EP2660315B1/en active Active
- 2011-12-27 US US13/976,524 patent/US9611458B2/en active Active
- 2011-12-27 EP EP16198419.0A patent/EP3147355B1/en not_active Revoked
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5725856A (en) | 1988-01-12 | 1998-03-10 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
JPH07506492A (ja) | 1992-05-09 | 1995-07-20 | ヴエストフアリア ゼパラトール アクチエンゲゼルシヤフト | 無菌培地の連続調合法 |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
WO1996030046A1 (en) | 1995-03-30 | 1996-10-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
WO1998051793A1 (en) | 1997-05-15 | 1998-11-19 | Genentech, Inc. | Apo-2 RECEPTOR |
JP2000217455A (ja) | 1999-01-28 | 2000-08-08 | Kubota Corp | イチゴ用液体培地組成物 |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
JP2003250533A (ja) | 2002-03-05 | 2003-09-09 | F Hoffmann La Roche Ag | 哺乳類細胞をインビトロで増殖させる改善法 |
JP2006500931A (ja) * | 2002-09-30 | 2006-01-12 | ファイザー・プロダクツ・インク | 高レベルのヒト配列抗体を産生するハイブリドーマ |
WO2005017130A2 (en) | 2003-08-18 | 2005-02-24 | Glycotope Gmbh | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof |
WO2010008075A1 (ja) | 2008-07-17 | 2010-01-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
WO2010036774A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for purification of viruses |
WO2010036760A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
Non-Patent Citations (72)
Title |
---|
"Book of Abstracts of The 23rd Annual and International Meeting of the Japanese Association for Animal Cell Technology", September 2010, pages: 127 |
"Filter Sterilization of Samples (1- 100 mL) in Sterile Acrodisc (Registered trademark) Syringe Filters.5.3", 15 November 2010, PALL CORPORATION |
ANTICANCER RES., vol. 13, 1993, pages 331 |
BIOPHARM, vol. 46, September 2006 (2006-09-01) |
BRITISH J. CANCER, vol. 83, 2000, pages 493 |
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 260 |
CANCER RES., vol. 54, 1994, pages 1511 |
CANCER RES., vol. 55, no. 23, 1995, pages 5935S - 5945S |
CANCER RES., vol. 57, 1997, pages 4593 |
CANCER, vol. 88, 2000, pages 2909 |
CELL, vol. 6, 1975, pages 121 |
CHROMOSOMA, vol. 41, 1973, pages 129 |
CIRCULATION, vol. 101, 2000, pages 1158 |
CURR. OPIN. ONCOL., vol. 10, 1998, pages 548 |
CYTOKINE, vol. 3, 1991, pages 562 |
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 |
GENES DEVELOP., vol. 4, 1990, pages 1288 |
GENETICS, vol. 55, 1968, pages 513 |
HYBRIDOMA, vol. 13, 1994, pages 183 |
IMMUNOL. REV., vol. 127, 1992, pages 5 |
J. BIOCHEM., vol. 101, 1987, pages 1307 |
J. BIOL. CHEM., vol. 252, 1977, pages 1998 |
J. BIOL. CHEM., vol. 252, 1977, pages 5558 |
J. BIOL. CHEM., vol. 258, 1983, pages 9017 |
J. BIOL. CHEM., vol. 265, 1990, pages 16455 |
J. BIOL. CHEM., vol. 272, 1997, pages 17400 |
J. CLIN. MICROBIOL., vol. 37, 1999, pages 396 |
J. EXP. MED., vol. 173, 1992, pages 269 |
J. EXP. MED., vol. 186, 1997, pages 1373 |
J. EXPERIMENTAL MEDICINE, vol. 147, 1978, pages 923 |
J. IMMUNOL. METHODS, vol. 217, 1998, pages 41 |
J. IMMUNOL., vol. 152, 1994, pages 2968 |
J. LEUC. BIOL., vol. 55, 1994, pages 280 |
J. NEUROSCI. RES., vol. 40, 1995, pages 647 |
J. RHEUMATOLOGY, vol. 25, 1998, pages 2065 |
J. UROLOGY, vol. 160, 1998, pages 2396 |
JOURNAL OF DENTAL RESEARCH, vol. 46, no. 3, May 1967 (1967-05-01), pages 514 - 521 |
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 108, 1958, pages 945 |
LOWE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 8227 |
METHODS IN CELL SCIENCE, vol. 18, 1996, pages 115 |
MOLECULAR CELLGENETICS, APPENDIX I, II, pages 883 - 900 |
MOLECULAR IMMUNOL., vol. 31, 1994, pages 371 |
MOLECULAR IMMUNOL., vol. 36, 1999, pages 387 |
MOLECULAR PHARMACOL., vol. 58, 2000, pages 237 |
NATURE REVIEWS DRUG DISCOVERY, vol. 3, May 2004 (2004-05-01), pages 383 |
NATURE, vol. 329, 1987, pages 840 |
NATURE, vol. 339, 1989, pages 487 - 488 |
NATURE, vol. 369, 1994, pages 533 |
NATURE, vol. 400, 1999, pages 776 |
ONCOGENE, vol. 19, 2000, pages 2138 |
PAULSON ET AL., JBIOL.CHEM., vol. 264, 1989, pages 17619 |
PERI ET AL., J. IMMUNOL. METH., vol. 174, 1994, pages 249 |
PROC. NATL. ACAD. SCI, USA, vol. 77, 1980, pages 4216 |
PROC. NATL. ACAD. SCI. USA, vol. 53, 1965, pages 288 |
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 1275 |
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 |
PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 9911 |
PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 |
PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 |
PROC. NATL. ACAD. SCI., vol. 60, 1968, pages 1275 |
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1 |
RADIATION RESEARCH, vol. 148, 1997, pages 260 |
SCIENCE, vol. 122, 1952, pages 501 |
SCIENCE, vol. 193, 1976, pages 1007 |
SCIENCE, vol. 253, 1991, pages 1129 |
See also references of EP2660315A4 |
STRUCTURE, vol. 8, 2000, pages 385 |
THE JOURNAL OF RHEUMATOLOGY, vol. 33, November 2006 (2006-11-01), pages 2124 - 2131 |
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
VIROLOGY, vol. 52, 1973, pages 456 |
VIROLOGY, vol. 8, 1959, pages 396 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2019088143A1 (ja) * | 2017-11-01 | 2020-11-12 | 中外製薬株式会社 | 生物活性が低下した抗体バリアントおよびアイソフォーム |
WO2020091041A1 (ja) * | 2018-11-02 | 2020-05-07 | 協和キリン株式会社 | 液体培地の調製方法 |
JPWO2020091041A1 (ja) * | 2018-11-02 | 2021-09-30 | 協和キリン株式会社 | 液体培地の調製方法 |
JP7453151B2 (ja) | 2018-11-02 | 2024-03-19 | 協和キリン株式会社 | 液体培地の調製方法 |
Also Published As
Publication number | Publication date |
---|---|
US9611458B2 (en) | 2017-04-04 |
US20130267684A1 (en) | 2013-10-10 |
JP5882913B2 (ja) | 2016-03-09 |
JPWO2012091023A1 (ja) | 2014-06-05 |
ES2710543T3 (es) | 2019-04-25 |
EP3147355A1 (en) | 2017-03-29 |
EP2660315B1 (en) | 2018-11-14 |
ES2812923T3 (es) | 2021-03-18 |
EP2660315A1 (en) | 2013-11-06 |
EP3147355B1 (en) | 2020-07-22 |
EP2660315A4 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6943972B2 (ja) | 灌流培地 | |
US20130130317A1 (en) | Method for producing substance | |
JP6797950B2 (ja) | 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現 | |
TW202035687A (zh) | 突變型piggyBac轉位酶 | |
JP7453151B2 (ja) | 液体培地の調製方法 | |
JP5882913B2 (ja) | 培地およびキレート剤を含む水溶液の調製方法 | |
JP7032438B2 (ja) | 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法 | |
WO2008035631A1 (fr) | Procédé de production d'une substance | |
WO2022225060A1 (ja) | 分解物の産生を抑制する方法 | |
US9976163B2 (en) | Method for preventing reduction of polypeptide by adding amino acid to culture solution | |
WO2006109781A1 (ja) | 糖タンパク質組成物の製造方法 | |
US20240209115A1 (en) | Methods for reducing low molecular weight species of recombinantly-produced proteins | |
US20240010737A1 (en) | Manufacturing process for high titer antibody | |
WO2020122048A1 (ja) | 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法 | |
WO2020122049A1 (ja) | 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法 | |
JP2023538581A (ja) | 細胞培養プロセス | |
US20050175599A1 (en) | Process for producing substance | |
JP2010536345A (ja) | 新規な方法および細胞系 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11854382 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012550988 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13976524 Country of ref document: US Ref document number: 2011854382 Country of ref document: EP |